Full Breakdown
Breakthrough mRNA Cancer Vaccine Shows Promise in Melanoma Trial
8/24/2026, 7:50:36 PM
Core Event: Phase 3 INTerpath-001 Results
Moderna and Merck announced that their personalized mRNA cancer vaccine, intismeran autogene, combined with Merck’s immunotherapy Keytruda (pembrolizumab), met the primary endpoint of recurrence-free survival (RFS) and the key secondary endpoint of distant metastasis-free survival (DMFS) in the Phase III INTerpath-001 trial. The study enrolled 1,137 patients with stage IIB-IV melanoma whose tumors had been completely resected and who had not received prior systemic therapy. Participants received up to nine vaccine doses while continuing Keytruda for about one year.
Background & Context
The vaccine builds on mRNA technology first deployed for COVID-19. Unlike traditional vaccines, intismeran is therapeutic and personalized: tumor DNA is sequenced, up to 34 neoantigen-encoding mRNA fragments are selected, and a bespoke vaccine is manufactured for each patient. Earlier Phase IIb data showed a durable hazard-ratio reduction in recurrence, prompting the larger trial.
Data & Statistics
- Enrollment: 1,137 patients (stage IIB-IV melanoma).
- Arms: Keytruda alone vs. Keytruda + intismeran.
- Dosing: Up to nine vaccine injections per patient in the combination arm.
- Efficacy: The combination improved both RFS and DMFS; Phase IIb results indicated a 49 % reduction in recurrence or death and a 59 % reduction in distant metastasis or death.
- Safety: No new safety concerns were identified; detailed adverse-event data remain unpublished.
- Market reaction: Moderna shares rose 177 % on the announcement day, while Merck’s stock jumped nearly 13 % to an all-time high.
Official Statements & Responses
Merck’s research laboratory president, Dean Y., said the full data will be presented at an upcoming international oncology conference and submitted to the U.S. Food and Drug Administration for review.
Criticism & Opposition
Daina M. Graybosch, PhD, senior managing director of immuno-oncology at Leerink Partners, cautioned that market enthusiasm may be “overly optimistic” and that the vaccine’s high per-patient manufacturing cost could limit gross margins. She noted that melanoma’s high tumor mutational burden may not translate to other solid tumors, making broader sales forecasts uncertain.
Why It Matters / Impact
If regulatory approval follows, intismeran could become the first approved mRNA-based therapeutic cancer vaccine, expanding mRNA’s use beyond infectious diseases. The trial demonstrates that personalized neoantigen vaccines can achieve statistically significant clinical benefits in a large, late-stage study—a milestone that may accelerate development of similar approaches for other cancers. Successful commercialization would also diversify Moderna’s revenue away from its COVID-19 portfolio.
Verbatim Quotes
- “Thirty-four is quite a lot of chances, of shots on goal,” — Jane Healy, head of oncology early development at Merck
What's Next
The companies plan to present the complete trial findings at an upcoming scientific meeting, with regulators expected to review the data for potential approval. Ongoing studies are evaluating intismeran in non-small cell lung cancer, bladder cancer, renal cell carcinoma and other solid tumors.
